Bayer Aktiengesellschaft

SWX:BAYN Stock Report

Market Cap: CHF 42.6b

Bayer Valuation

Is BAYN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of BAYN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BAYN (CHF36.29) is trading below our estimate of future cash flow value (CHF172.4)

Significantly Below Future Cash Flow Value: BAYN is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BAYN?

Key metric: As BAYN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BAYN. This is calculated by dividing BAYN's market cap by their current revenue.
What is BAYN's PS Ratio?
PS Ratio1x
Sales€45.24b
Market Cap€46.17b

Price to Sales Ratio vs Peers

How does BAYN's PS Ratio compare to its peers?

The above table shows the PS ratio for BAYN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.6x
SDZ Sandoz Group
3.4x5.23%CHF 31.1b
GALD Galderma Group
9.9x13.62%CHF 41.8b
ROP Roche Holding
4.2x3.24%CHF 268.0b
NOVN Novartis
5x5.02%CHF 231.2b
BAYN Bayer
1x2.24%CHF 46.2b

Price-To-Sales vs Peers: BAYN is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (5.6x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does BAYN's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

18 CompaniesPrice / SalesEstimated GrowthMarket Cap
BAYN 1.0xIndustry Avg. 4.1xNo. of Companies24PS048121620+
18 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BAYN is good value based on its Price-To-Sales Ratio (1x) compared to the European Pharmaceuticals industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is BAYN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BAYN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BAYN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BAYN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 36.29
CHF 47.60
+31.18%
10.96%CHF 59.92CHF 37.34n/a18
Jun ’27n/a
CHF 45.25
0%
13.86%CHF 54.87CHF 27.44n/a19
May ’27CHF 33.97
CHF 44.77
+31.80%
17.75%CHF 55.42CHF 23.09n/a19
Apr ’27n/a
CHF 42.84
0%
21.91%CHF 55.00CHF 21.08n/a19
Mar ’27CHF 38.30
CHF 41.18
+7.52%
25.57%CHF 54.75CHF 20.99n/a20
Feb ’27n/a
CHF 38.62
0%
27.00%CHF 50.42CHF 21.09n/a20
Jan ’27n/a
CHF 31.81
0%
20.18%CHF 46.53CHF 21.40n/a19
Dec ’26n/a
CHF 27.83
0%
15.03%CHF 36.44CHF 21.49n/a19
Nov ’26n/a
CHF 26.44
0%
14.14%CHF 36.18CHF 21.34n/a19
Oct ’26n/a
CHF 26.66
0%
14.27%CHF 36.44CHF 21.49n/a19
Sep ’26n/a
CHF 26.86
0%
14.27%CHF 36.72CHF 21.66n/a19
Aug ’26n/a
CHF 26.45
0%
14.39%CHF 36.36CHF 21.44n/a19
Jul ’26n/a
CHF 26.58
0%
17.61%CHF 42.13CHF 20.55n/a20
Jun ’26n/a
CHF 25.79
0%
18.73%CHF 42.13CHF 18.68n/a20
May ’26n/a
CHF 25.61
0%
20.21%CHF 42.28CHF 18.75CHF 33.9720
Apr ’26n/a
CHF 26.37
0%
19.72%CHF 43.16CHF 21.05n/a20
Mar ’26n/a
CHF 24.95
0%
18.80%CHF 37.55CHF 20.65CHF 38.3019
Feb ’26n/a
CHF 25.29
0%
18.86%CHF 37.76CHF 20.77n/a19
Jan ’26n/a
CHF 25.47
0%
18.65%CHF 37.59CHF 20.67n/a19
Dec ’25n/a
CHF 25.34
0%
18.12%CHF 37.17CHF 20.45n/a19
Nov ’25n/a
CHF 30.87
0%
23.22%CHF 57.05CHF 23.38n/a19
Oct ’25CHF 67.99
CHF 30.79
-54.71%
23.00%CHF 57.70CHF 23.65n/a20
Sep ’25CHF 67.99
CHF 31.99
-52.95%
29.55%CHF 60.47CHF 23.62n/a21
Aug ’25CHF 67.99
CHF 33.16
-51.23%
29.07%CHF 61.89CHF 24.18n/a21
Jul ’25CHF 179.00
CHF 33.58
-81.24%
28.60%CHF 61.99CHF 24.21n/a21
Jun ’25CHF 190.00
CHF 34.38
-81.90%
28.90%CHF 62.62CHF 24.46n/a21
CHF 39.87
Fair Value
9.0% undervalued intrinsic discount
18
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/27 19:03
End of Day Share Price 2026/06/24 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bayer Aktiengesellschaft is covered by 41 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rafael Bonardell TrianesBanco de Sabadell. S.A.
Mark PurcellBarclays
Charles PitmanBarclays